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Summary sentence: This review summarizes the established and emerging roles of 
heparan sulfate as an immune regulator through its ability to bind numerous 
inflammatory ligands both in the microenvironment and on the cell-surface of 
leukocytes.  
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Abstract: Heparan sulfate is found on the surface of most cell types, as well as in 
basement membranes and extracellular matrices. Its strong anionic properties and 
highly variable structure enable this glycosaminoglycan to provide binding sites for 
numerous protein ligands, including many soluble mediators of the immune system, 
and may promote or inhibit their activity. The formation of ligand binding sites on 
heparan sulfate occurs in a tissue- and context-specific fashion through the action of 
several families of enzymes, most of which have multiple isoforms with subtly 
different specificities. Changes in the expression levels of these biosynthetic enzymes 
occur in response to inflammatory stimuli, resulting in structurally different HS and 
acquisition or loss of binding sites for immune mediators. In this review, we discuss 
the multiple roles for HS in regulating immune responses, and the evidence for 
inflammation-associated changes to HS structure.  
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1 Introduction 
Heparan sulfate (HS) is a ubiquitious but highly structurally variable 
polysaccharide found on cell surfaces and in extracellular matrices, conjugated to one 
of several types of core protein. Due to its strong anionic properties and the numerous 
possible combinations of modifications, heparan sulfate can bind to over 400 soluble 
protein mediators and cell-surface receptors (1), with disparate effects on their 
activity.  
 
HS plays well-established roles in the formation of chemokine gradients on 
the vascular endothelium and in regulating the activity of chemokines, cytokines and 
growth factors through physical sequestration in the matrix and protection from 
enzymatic proteolysis (recently reviewed in (2)). Here, we briefly outline our current 
knowledge of the role of HS in these processes, then discuss other currently less 
appreciated roles for HS in immune regulation, including direct signaling through 
TLR4, involvement in phagocytosis, and regulating the interaction of inflammatory 
mediators with their receptors. HS additionally functions in self versus non-self 
discrimination by the innate immune system through its role as a regulator of the 
alternative pathway of complement activation, which is reviewed in a number of 
excellent publications (3-5). Here again, it is the structural variability of HS that 
enables it to perform various functions in a tissue- and context-specific manner, acting 
either as an inhibitor of the complement cascade through binding factor H on self 
surfaces and thus accelerating C3b inactivation, or as an activator through binding the 
stabilizing factor properdin on apoptotic cells. 
 
 
 4 
Heparan sulfate is found covalently attached to one of several types of core 
protein, thus forming proteoglycans. The two most abundant types of cell-surface 
heparan sulfate core protein are the trans-membrane syndecans and the GPI-anchored 
glypicans, but others such as the secreted proteins perlecan and agrin are also 
decorated with HS. In addition, some proteins, such as isoform 3 of the hylaruonan 
receptor (CD44), and betaglycan  (TGFβR3) are ‘part-time HSPGs’ in that they bear 
HS chains in certain tissues or under certain conditions. HS biosynthesis occurs in the 
Golgi network via the combined actions of more than 25 enzymes, which has been 
recently and comprehensively reviewed (6). Briefly, biosynthesis begins with the 
assembly of a tetrasaccharide linkage region at glycosaminoglycan (GAG) attachment 
sites on the core protein, then the linear HS polysaccharide backbone is elongated by 
the sequential addition of alternating glucuronic acid and N-acetylglycosamine 
residues, catalysed by enzymes of the EXT family. Concurrently, HS chains undergo 
extensive enzymatic modification beginning with N-de-acetylation/N-sulfation, and 
epimerization of some glucuronic acid residues to iduronic acid by the D-glycuronyl 
C5-epimerase (GLCE). Sequence complexity is further increased by sulfation at 
various positions by 2-O-, 3-O-, and 6-O-sulfotransferases that act in a template-
independent manner, producing a varied and hetereogenous structure (Figure 1). The 
requirement for previous modifications to form the substrate for subsequent reactions 
results in highly sulfated domains flanked by less sulfated transition zones, separated 
by regions of little or no modification.  
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How HS structure is regulated is poorly understood, but as most of the 
modifying enzymes have multiple isoforms with different substrate specificities (7), it 
is thought that cells may regulate the structure of their HS by altering the relative 
expression levels of the modifying enzymes (8). 
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2 HS in the microenvironment regulates the activities of immune cells 
 
HS is an important component of basement membranes and the extracellular matrix, 
where it immobilizes a variety of ligands. This can have a range of functional 
consequences including local retention, regulation of receptor interactions, and 
protection from the actions of proteases, as discussed below and illustrated in Figure 
2. In addition, heparan sulfate can itself be a ligand for certain receptors involved in 
leukocyte recruitment to inflammatory sites.  
 
2.1 HS immobilizes chemokines on vascular and lymphatic endothelium 
Circulating blood leukocytes such as monocytes and neutrophils are 
stimulated to crawl along the endothelium towards inflammatory sites by an 
immobilized gradient of chemokines, a process called haptotaxis or chemotaxis. More 
than 40 chemokines have been identified, all of which have been shown or are 
predicted to bind heparin or heparan sulfate (1). It is thought that a major role of 
endothelial heparan sulfate is to form a concentration gradient that directs the 
migration of leukocytes by immobilizing chemokines and preventing them being 
washed away by the blood flow (Figure 2).  This hypothesis is supported by 
observations that mutant chemokines lacking the ability to bind heparan sulfate fail to 
recruit leukocytes in vitro and in vivo (9), (10) (11). Moreover, heparanase-
overexpressing mice, which have very short heparan sulfate chains, show impaired 
neutrophil crawling in response to WT chemokines (12), further demonstrating the 
importance of the chemokine-GAG interaction.  
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It has also been observed that many chemokines oligomerize on heparan 
sulfate and that the ability to form oligomers is required to achieve maximal local 
concentrations (13). Oligomerization, as well as ability to bind heparan sulfate, 
appears to be critical for the activity of certain chemokines, as monomeric mutants of 
RANTES, MIP-1β and MCP-1 have severely reduced chemotactic activity in vivo 
when injected IP into mice despite unchanged affinity for their receptors (10).  
 
 The variation of HS structure in different tissues may be relevant to 
chemokine binding; for example, the HS from aortic and venous endothelial cells 
differs in degree of sulfation (14) which results in the formation of binding sites for 
chemokines only at post-capillary venules and small veins, where leukocyte 
emigration occurs, and not in capillaries and arteries (15, 16). Chemokine binding to 
HS also has some tissue specificity, as demonstrated by the retention of IL-8 in the 
lungs but not the skin (13). These findings suggest that HS-mediated control of 
chemokine binding might determine to which sites leukocytes are recruited. 
Furthermore, it is possible that dynamic regulation of HS during inflammation 
modulates chemokine gradients and thus chemotaxis. In support of this, staining for 
HS in high endothelial venules of the lymph node revealed more HS on the 
basolateral side than the luminal side, and increased deposition of HS on only the 
basolateral side after stimulation with Total Freund’s Adjuvant (17). Thus HS may 
facilitate formation of a trans-epithelial chemokine gradient that becomes more 
pronounced during inflammation.  
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2.2 Endothelial HS as a ligand for leukocyte selectins 
In addition to their role in the presentation of chemokines, heparan sulfate 
proteoglycans are more directly involved in leukocyte recruitment through their 
capacity to act as ligands for selectins (Figure 2), thus facilitating leukocyte rolling 
and adhesion (reviewed in (18)). The nature of this interaction has been difficult to 
unravel since HS is present on both endothelial cells and leukocytes, and selectins are 
also expressed by both cell types: leukocytes constitutively express L-selectin, 
whereas endothelial cells upregulate P-selectin upon activation.  
 
In vitro studies using endothelial monolayers in flow chambers to mimic the 
physiological shear stress of blood vessels have provided evidence of a role for HS in 
leukocyte recruitment. For example, digesting HS from endothelial monolayers with 
heparinase III, or adding heparin or soluble HS to the medium, significantly reduces 
the number of rolling and firmly adhering granulocytes (19), and the total HS 
deficiency resulting from knockdown of Ext1 in HUVECs prevents normal neutrophil 
arrest and transendothelial migration (20). Similarly, genetic inactivation of Ndst1 in 
endothelial cells inhibits granulocyte adhesion to endothelial monolayers and is also 
associated with decreased binding of recombinant L-selectin (21) suggesting that HS 
is a physiological ligand for this adhesion molecule. Further supporting this 
hypothesis, pre-treatment of monocytes with an L-selectin-blocking antibody inhibits 
their adhesion to endothelial monolayers (22), while the binding of recombinant L-
selectin to HEV in tissue sections from various organs is sensitive to heparinase 
digestion (23). 
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In vivo studies also imply a major role for the HS-L-selectin interaction in 
leukocyte recruitment in various inflammatory models. Heparin infusion dramatically 
inhibits neutrophil infiltration into the peritoneal cavity following thioglycollate 
injection, and reduced ear thickness and inflammatory cell infiltrate in a contact 
dermatitis model (24). Importantly, L- and P-selectin doubly-deficient mice showed 
no further decrease in leukocyte recruitment following heparin treatment, confirming 
that heparin inhibits inflammation primarily through these two selectins (24). 
Similarly, the reduced HS sulfation achieved by conditional deletion of Ndst1 from 
only endothelial cells and leukocytes results in reduced leukocyte recruitment in 
models of peritonitis (25), allergen-induced airway remodelling (26, 27), and diabetic 
(28) and experimental (21) glomerulonephritis. Of particular interest was the 
observation that chimeric WT mice with Ndst1-null bone marrow do not show any 
defect in thioglycollate-induced lymphocyte homing, whereas KO mice given WT 
bone marrow show the same reduction in cell infiltrate seen in the mice lacking both 
endothelial and leukocyte Ndst1 (25). Conversely, the compensatory increase in N- 
and 6-O-sulfation resulting from endothelial Hs2st deletion leads to increased 
leukocyte recruitment that is returned to control levels by an L-selectin-blocking 
antibody (29).  These results imply that the crucial interaction is that between the 
sulfated motifs of endothelial HS and leukocyte L-selectin, whereas leukocyte HS and 
P-selectin have little effect in this context.  
 
However, while most data indicate that endothelial HS promotes leukocyte 
adhesion through L-selectin, some studies suggest that HS may have an inhibitory 
effect on leukocyte attachment. For example, heparinase digestion of microperfused 
murine venules results in more adherent leukocytes (30) and increased binding of 
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fluorescently-labelled microspheres coated with anti-ICAM-1 antibody (31), implying 
that the HS layer might inhibit leukocyte binding by masking endothelial adhesion 
molecules and making them less accessible to leukocyte integrins (Figure 2). In 
support of this, intravital microscopy showed that the loss of endothelial glycocalyx 
following LPS infusion led to increased adhesion of GFP+ neutrophils and of anti-
ICAM-1 microspheres in WT but not heparanse-null mice (32). These results suggest 
that heparanase-mediated shedding of endothelial HS in response to a potent 
inflammatory stimulus may expose more adhesion molecules such as ICAM-1. Thus 
HS may play two separate roles in leukocyte recruitment: directly by facilitating 
selectin-mediated leukocyte attachment and rolling, and indirectly through regulating 
accessibility of other adhesion ligands such as ICAM-1. Further studies are thus 
required to determine the relative contributions made by HS as a selectin ligand, and 
as a barrier to ICAM-1 accessibility, over time during the phases of initiation and 
resolution of an immune response.  
 
Given the multi-faceted role for endothelial HS in leukocyte recruitment, one 
might expect the structure of HS to be altered in response to inflammatory stimuli or 
tissue damage in order to regulate immune cell infiltration, and there is evidence that 
this is indeed the case. For example, endothelial HS sulfation is increased by in vitro 
stimulation with TGF-β (33), IFN-γ (34), IL-1β (35), or TNF (36) with associated 
upregulation of Ndst1, 2, Hs6st1 and 2 (36), and increased ability to bind L-selectin 
(22) and support the arrest and adherence of leukocytes (19). In vivo, renal 
ischemia/reperfusion stimulates the formation of binding sites for L-selectin in the 
interstitial capillaries that are not present in the contralateral control kidney (37). 
Experimentally induced nephritis is associated with increased expression of highly 
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sulfated HS domains (38), which are also seen in kidney sections from SLE patients 
and MRL/lupr mice (39) but not healthy controls. Thus it seems likely that 
dynamically regulating the structure of endothelial HS may be a mechanism to fine-
tune cell recruitment during an immune response. 
 
 2.3 HS in the ECM regulates activity of cytokines 
Cytokine activity is determined by a combination of factors including 
localization close to the target cell, susceptibility to inactivation by proteolytic 
cleavage, and ability to interact with high affinity receptors. Numerous cytokines have 
been demonstrated to bind heparin or HS in vitro (1) but the biological consequences 
of this interaction for cytokine activity have been explored for only a few cytokines. 
The available data indicate that HS exerts diverse effects on different cytokines, 
which is hardly surprising given the structural heterogeneity in this functional class of 
molecules.  
 
Although often described as soluble mediators, cytokines exert their effects 
locally not systemically and binding to ECM heparan sulfate has been proposed as a 
mechanism for retaining cytokines close to their site of production and action. For 
example, endogenous IL-2 is detectable in murine spleen, liver sinusoids, and kidney 
glomeruli, and staining is absent after treating the sections with heparitinase, but not 
with chondroitinase (40). Similarly, IFN-γ injected into rats rapidly disappears from 
the circulation and accumulates in specific tissues including the liver, spleen, and 
kidney, which is inhibited by co-injection with heparin (41). Thus, heparan sulfate 
immobilizes certain cytokines in the extracellular space, forming localized reservoirs 
that may facilitate paracrine signaling (Figure 2). 
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Whether HS-immobilized chemokines are able to interact with their receptor 
depends partly on whether the heparan- and receptor-binding sites overlap. Surface 
plasmon resonance experiments demonstrated that the binding of IFN-γ to its receptor 
or to HS are mutually exclusive (42), which would imply that immobilized IFN-γ in 
the matrix cannot signal. However, endothelial monolayers pulsed with IFN-γ 
stimulate MHC-II upregulation by co-incubated target cells which is abolished by 
heparinase II treatment (43), suggesting that cell-surface HS might present IFN-γ in 
trans in a signalling-competent manner. Whether HS-bound IFN-γ must dissociate 
from the matrix to bind its high-affinity receptor, or can bind both simultaneously, 
remains unresolved. It was recently demonstrated for IL-2 that reservoirs on 
endothelial and smooth muscle cells of blood vessels are liberated by heparanase in a 
biologically active form that is competent to stimulate target cell proliferation (44). 
Thus changes to the matrix that occur during inflammation may release cytokines 
from ECM reservoirs and enable them to signal. 
 
In addition to regulating availability of soluble cytokine, HS may also 
influence cytokine activity by controlling their accessibility to proteases (Figure 2). 
For example, proteolytic cleavage of the C-terminal portion of IFN-γ increases 
receptor binding if fewer than ten terminal amino acids are removed (42), but binding 
is decreased by larger deletions (45). Heparin and highly sulfated HS bind IFN-γ at its 
C-terminus (46), and co-injection of heparin protects IFN-γ from proteolytic 
degradation in vivo (47). Heparin has also been shown to prevent degradation of other 
cytokines including IL-6 (48) and IL-7 (49) in vitro. Thus binding to matrix HS may 
serve to protect the active form of the cytokine, as well as forming local reservoirs.  
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Soluble HS fragments released in inflammation may also regulate signalling 
of some cytokines by promoting their interaction with receptors on target cells. It has 
been demonstrated that addition of soluble HS to cells that lack detectable levels of 
this GAG on their surface augments IL-5-induced proliferation (50), and IL-12-
stimulated IFN-γ production (51). The mechanism by which soluble HS promotes 
signalling of these cytokines has not been explored, and the relevance of these 
observations to inflammatory processes in vivo is not yet clear.  
 
 
3 Soluble HS directly stimulates immune cells, acting on APCs to 
control immune responses  
HS fragments liberated from the extracellular matrix by enzymes released during 
inflammation can promote immune activation by signalling through TLR4 and 
activating APCs. 
 
3.1 Heparan sulfate is degraded in inflammation to become a potent TLR4 
ligand. 
It has become evident that soluble fragments of HS can signal through toll-like 
receptor 4 (TLR4), an innate pattern recognition receptor for which the prototypic 
ligand is bacterial lipopolysaccharide (LPS). Stimulation of DCs with HS fragments 
induces upregulation of co-stimulatory molecules including CD86 and CD40 and 
secretion of pro-inflammatory cytokines (52), which is inhibited by TLR4 mutation or 
the TLR4 antagonist Rs-DPLA (53). These findings suggest that HS is a non-classical 
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ligand for TLR4 that is capable of signalling to trigger immune activation (Figure 3). 
Similarly, cardiac fibroblasts stimulated with HS upregulate V-CAM1 and I-CAM1, 
leading to increased adhesion of PMNs and SMCs, which is completely abolished by 
the TLR4 inhibitor TAK-242 or by blocking the downstream signalling molecules 
NFkB or PI3K/Akt (54). 
 
Proliferation of T cells after co-incubation with allogeneic DCs is augmented by 
soluble HS, but not when the DCs come from mice deficient in TLR4 or its adaptor 
protein MyD88. However, knockout of these molecules in T cells had no effect (55), 
and HS treatment of purified T cells stimulated with anti-CD3 in the absence of DCs 
did not augment proliferation (56), demonstrating that HS indirectly controls 
lymphocyte activity through regulating APC maturation. Furthermore, murine 
peritoneal macrophages stimulated with HS upregulate IL-1, IL-6, TNF, and IL-12, 
and show increased cytotoxicity towards a leukemia cell line (57). In vivo evidence 
for the role of the HS-TLR4 axis in inflammation comes from infusion of soluble HS 
into the pancreas of mice which results in neutrophil infiltration and increased 
myeloperoxidase (MPO) activity in WT but not TLR4-null mice (58).  
 
It is thought that the elevated activity of metalloproteases (59), heparanase (60)  
and other enzymes that occurs in inflammation liberates HS fragments from cell-
surface and extracellular matrix HSPGs. These soluble HS fragments could then 
signal through TLR4 to alert the immune system to tissue damage, thus acting as a 
damage-associated molecular pattern (DAMP). In support of this hypothesis, 
endothelial cells with metabolically labelled sulfated GAGs show a decrease in cell-
surface HS and an increase in smaller HS fragments in the conditioned medium upon 
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LPS stimulation (61) or exposure to activated neutrophils, which can be reduced by 
inhibitors of serine proteases and elastase (62). Furthermore, heparanase treatment of 
human PBMCs resulted in a reduction of cell-surface HS and an upregulation of pro-
inflammatory cytokines similar to that seen by addition of HS fragments, which was 
abrogated by inhibitors of heparanase or by MyD88 or TLR4 deficiency (63).  
 
In vivo, administration of the serum protease inhibitor alpha-1 anti-trypsin 
(A1AT) to recipients of allogeneic bone marrow transplants increased survival and 
lowered serum HS and histological scores. Furthermore, while TLR4 gene deletion 
conferred some protection from graft-versus-host disease, no further benefit was seen 
with A1AT treatment (55), indicating that the protective effects of A1AT are 
mediated through the HS-TLR4 axis. Similarly, injection of elastase into WT mice 
induced loss of HS from blood vessels, an increase in serum TNF and ultimately 
death of the mice, whereas TLR4-null mice showed improved survival (64). 
Collectively, these results suggest a pathway in which fragments of HS produced 
enzymatically during inflammation signal through TLR4 to further activate the 
immune system, which may have beneficial or detrimental effects depending on the 
context.  
 
There is evidence to suggest that the immune system is able to distinguish 
between endogenous stimuli indicative of tissue damage and exogenous stimuli 
present as a result of infection, enabling a context-appropriate response to be 
mounted. For example, macrophages stimulated with LPS or the matrix glycoprotein 
tenacin-C, which is produced upon tissue injury and also signals through TLR4, 
resulted in different transcriptional responses and two distinct macrophage 
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phenotypes (65). LPS-stimulated macrophages had greater collagen-degrading ability 
and inflammatory cytokine production, whereas tenacin-C treatment induced 
macrophages to synthesise collagens and other proteins associated with tissue repair. 
One might thus predict that HS, another endogenous DAMP that signals through 
TLR4, also stimulates an immune response different to that induced by LPS. In 
support of this, the kinetics of TLR4 signalling in response to LPS or HS are different, 
with LPS inducing much more rapid nuclear translocation of NFkB than HS (53) and 
HS triggering a slower and more sustained increase in intracellular calcium (66). 
Further studies are required to define how TLR4 signalling induced by endogenous 
DAMPs such as HS is different to that induced by infection-associated stimuli such as 
LPS, and whether this results in context-appropriate responses from the immune cell.  
4 HS on leukocyte surface regulates their immune and inflammatory 
functions Although frequently considered a matrix molecule, HS is expressed on the surface of most cells, including immune cells, in the form of proteoglycans. In addition to regulating receptor interactions both cell autonomously and through ligand presentation to other cells, leukocyte cell-surface HS appears to contribute to specific functions such as phagocytosis. This may be a physiologically relevant mechanism of immune regulation, as the structure of leukocyte HS is altered in response to various inflammatory stimuli.  
 
4.1 Leukocyte HS promotes phagocytic activity 
Cell-surface HS is thought to be involved in recognition and uptake of dead 
cells by phagocytes through exposure of HS binding sites on late apoptotic and 
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necrotic cells that have lost membrane integrity (Figure 3). For example, FITC-
labelled heparin was found to bind to the surface of apoptotic and necrotic cells, but 
not live cells, and this interaction was inhibitable by heparin but not dermatan or 
chondroitin sulfates (67). Beads coated with anti-HS antibodies were bound and 
internalized by epithelial cell lines, but not if the cells had been pre-treated with 
heparinase III or in the presence of inhibitors of PKC or actin polymerization (68), 
suggesting that ligation of cell-surface HS is sufficient to stimulate actin-mediated 
endocytosis in non-professional phagocytes. Similarly, CHO cells and human skin 
fibroblasts bind and internalize latex beads, and this is strongly reduced by the 
addition of heparin or soluble HS fragments or by pre-treatment of the cells with 
heparinase III (69). Additionally, CHO mutant cells lacking the ability to synthesise 
HS showed defective binding and internalization of the beads, adding further support 
to an HS-mediated mechanism of phagocytosis. These studies were performed in 
largely artificial systems with non-professional phagocytes, but there is some 
evidence that an HS-dependent mechanism of phagocytosis is conserved in a relevant 
immune setting: human PMNs more efficiently bind and internalize a strain of H. 
pylori that can bind HS than a strain without HS-binding ability, and pre-incubation 
of the bacteria with heparin inhibited uptake of the HS-binding strain but did not 
further reduce uptake of the non-HS-binding strain (70) However, further studies are 
required to determine the relative contribution that HS makes as an endocytic receptor 
in the presence of canonical phagocytic receptors, antibodies and other opsonins that 
have an established role in phagocytosis in vivo (71). 
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4.2 Leukocyte HS regulates responses to inflammatory mediators 
 HS on the surface of leukocytes appears to play a role in regulating signaling 
of certain inflammatory mediators through their cell-surface receptors, either by 
promoting ligand interaction with its receptor, thus acting as a co-receptor, or by 
inhibiting receptor-ligand interactions, depending on the ligand (Figure 3). For 
example, the B cell activating factor APRIL, which is essential for IgA class 
switching in response to mucosal antigens (72), requires HS on the B cell surface for 
optimal receptor activation and downstream signalling. Heparinase III digestion of B 
cells strongly reduced APRIL-induced proliferation, IgA production, and NFkB 
translocation (73). APRIL can be competed off the B cell surface by heparin, and 
mutant forms of APRIL without HS-binding ability fail to stimulate IgA production 
by B cells (74). APRIL does not bind to the surface of Glce-/- B cells, which lack 
iduronic acid residues, and cannot promote their survival in vitro (75). This may be 
due to altered downstream modifications by the 2-O- and 6-O-sulfotransferases, 
whose activity is affected by epimerase inactivation (76). 
  
 Another B cell factor, IL-7, also binds heparin and HS, and IL-7-dependent 
proliferation is inhibited by the addition of heparin (49), suggesting that binding to 
cell-surface HS promotes IL-7 interacting with its receptor. In support of this, 
heparitinase treatment of primary B cell precursors diminished surface binding of IL-
7 and reduced IL-7-driven proliferation (77).  
 
Interleukin-10 (IL-10) binds both heparin and heparan sulfate, and the addition of 
soluble fragments of heparan sulfate inhibits the ability of IL-10 to upregulate CD64 
and CD16 on monocytes (78). Similarly, IL-10 induced expression of these markers is 
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inhibited by treatment of monocytes and macrophages with sodium chlorate, which 
prevents sulfation of GAGs (78), indicating that cell-surface HS promotes the 
interaction of IL-10 with its receptor. The crystal structure for IL-10 bound to IL-
10R1 shows no overlap with the GAG-binding site (79), but there is currently no 
crystal structure of the ternary complex composed of IL-10 and both receptor 
subunits. Therefore it remains unclear whether HS acts directly as a co-receptor in the 
formation of productive IL-10-IL-10R complexes, or simply facilitates IL-10 
signaling by preventing diffusion of the cytokine away from the cell surface.  
 
 Cells transfected with the splice variant of the hyaluronan receptor (CD44) 
containing HS attachment sites retain hepatocyte growth factor (HGF) on their cell 
surface, whereas no binding is seen on cells expressing the isoform of CD44 lacking 
the HS attachment region (80). The same study showed that ability to bind HGF on 
the surface resulted in phosphorylation of the HGF receptor tyrosine kinase c-Met, 
and of ERK-1 and ERK-2. Surface binding and signaling were abolished by 
heparitinase (but not chondroitinase ABC) treatment or by mutation of the HS-
binding domain of HGF, suggesting that HS-mediated capture of HGF on the cell 
surface facilitates receptor binding and activation. This appears to be a relevant 
mechanism in B cells since human tonsillar B cells activated by coincident ligation of 
CD40 and the BCR express a higher molecular weight form of CD44, with concurrent 
acquisition of HGF-binding ability. Downstream c-Met phosphorylation was 
abolished by heparitinase treatment of activated B cells (81), indicating that CD44 is 
decorated with HS following pro-inflammatory stimulation.  
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However, leukocyte HS may not always promote ligand-receptor interactions, as 
for certain ligands it acts instead as a barrier and inhibits signalling. Macrophages 
deficient in HS sulfation through deletion of Ndst1 show increased responsiveness to 
IFN-β stimulation and elevated production of pro-inflammatory cytokines and 
chemokines (82), suggesting that the role of HSPG in IFN-β signaling is to sequester 
it away from its receptor and thus maintain macrophages in a quiescent state.  
 
4.3 Leukocyte HS regulates cell activation in trans 
 In addition to these cell-autonomous functions, leukocyte cell-surface HS can 
also be involved in presentation of growth factors or inflammatory mediators 
produced by leukocytes to their target cells, as has been demonstrated for FGF-2 
(Figure 3). During monocyte-to-macrophage maturation, cells aquire the capacity to 
bind FGF-2, which is inhibitable by heparin and further augmented by stimulation 
with IL-1 or LPS (83). The same study showed that activated macrophages 
augmented the proliferative response of HS-deficient BaF32 cells to low 
concentrations of FGF-2, which was abolished by heparinase III treatment, indicating 
that macrophage HS enables trans-presentation of FGF-2 to target cells in a 
signalling-competent manner. Similarly, activated macrophages increase expression 
of the CD44v3 isoform of the hyaluronan receptor that contains HS chain attachment 
sites, and cell lines transfected with this HS-sufficient form of CD44, but not those 
with the HS-deficient variant, augmented FGF-2-induced proliferation of BaF32 cells 
(84). Interestingly, both studies found that T cells do not increase expression of 
CD44v3 or their total HS levels upon mitogenic stimulation, and T cells actually 
decrease HS expression and lose the ability to bind FGF-2 during consecutive rounds 
of proliferation (85). These observations suggest that HS-mediated trans-presentation 
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of growth factors may be a mechanism unique to those cells producing such growth 
factors upon activation. It remains to be determined whether modulation of HS 
expression regulates the activity of other HS-binding inflammatory mediators through 
surface presentation. 
 
4.4 Leukocyte HS structure is altered during inflammation 
 For leukocyte HS to be considered an active regulator of cell responses, it 
must itself be altered during the course of an immune response to facilitate changes in 
inflammatory processes, and there is increasing evidence that such dynamic 
regulation of HS does occur. B cells from virus-infected mice, or stimulated in vitro 
with the IFN-I-inducer Poly I:C or IFN-β, show increased surface expression of HS 
and augmented APRIL-induced production of IgA (86).  Similarly, stimulation with 
phorbol 12-myristate 13-acetate (PMA) or ligation of CD40 results in an increase in 
HS on the B cell surface and a switch to the higher molecular weight form of CD44 
that has HS chains (81). HS structure may also be regulated during B cell 
development, as ligation of the pre-BCR induces upregulation of numerous HS-
associated genes including Hs3st1 (87). Furthermore, microarray analyses of different 
B cell subsets show greater expression of HS biosynthetic enzymes in plasma cells 
than memory B cells (88), suggesting activation is associated with an increase in cell-
surface HS.  
 
Differential expression of HS is also a feature of macrophage subsets, as 
human monocyte-derived macrophages polarized to an anti-inflammatory reparative 
phenotype display greater upregulation of sulfotransferases than pro-inflammatory 
macrophages, resulting in more cell-surface HS with a higher degree of 2-O-sulfation 
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(89). Importantly, this differential expression of HS was shown to have functional 
consequences: reparative macrophages bound more FGF-2 and augmented FGF-2-
dependent proliferation of a target cell line, consistent with the requirement of 2-O-
sulfation for FGF-2 binding (90). This suggests that the expression of more highly 
sulfated HS in reparative macrophages may be important for their role in the 
resolution of inflammation. Various other stimuli have been reported to affect HS 
structure on macrophages, such as LPS and TNF which induce upregulation of 
HS3ST3B and consequently an increase in 3-O-sulfation (91), and hypoxia which 
significantly reduces expression of biosynthetic enzymes and total HS content (92). 
 
Interestingly, macrophages from the synovial fluid of RA and SLE patients 
show greater FGF-2 binding than blood monocytes (83), and CD44-HS splice variants 
were highly expressed in RA but not OA joints and co-localized with staining for 
macrophage markers and FGF-2 (84). These findings suggest that excessive growth 
factor activity seen during chronic inflammation may be partly due to aberrant 
regulation of leukocyte HS sulfation. 
 
5. Concluding remarks 
It is becoming increasingly apparent that HS has multiple roles in immune 
regulation and signalling during inflammation, both in the microenvironment and on 
the cell-surface of leukocytes. Soluble HS fragments also have signalling properties 
and may serve as indicators of tissue damage. Further studies are required for a better 
understanding of the changes in HS expression that occur during inflammation and 
the structural requirements for binding and regulation of immune mediators. 
Understanding these structure-function relationships will be essential for the 
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development of therapeutics that interfere these processes to combat 
immunopathology, which might take the form of synthetic HS oligosaccharides or 
HS-specific antibodies.  
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Figure 1. Heparan sulfate chains are extensively modified. Biosynthesis of 
heparan sulfate begins by attachment of a tetrasaccharide linkage region to the core 
protein (e.g. syndecan, glypican) and elongation of the polysaccharide backbone by 
alternate additions of glucuronic acid and N-acetylglucosamine residues by the EXT 
and EXTL enzymes. This is followed by N-deacetylation and N-sulfation of N-
acetylglucosamine residues by the NDST enzymes, and epimerization of some 
glucuronic acid residues to iduronic acid by the D-glucuronyl C5-epimerase GLCE. 
Sulfotransferase enzymes (HS2ST, HS3STs, HS6STs) then add sulfate groups at the 
2-O-, 3-O-, and 6-O- positions of the sugar ring. 
 
 
Figure 2. Heparan sulfate plays several roles in local acute inflammation. HS on 
the vascular endothelium binds chemokines and thus facilitates their oligomerization 
and presentation to circulating leukocytes, prevents them being washed away by the 
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blood flow, and forms the chemokine gradient necessary for directional migration of 
leukocytes. Endothelial HS may also directly regulate the recruitment of leukocytes 
by acting as a ligand for leukocyte L-selectin, or by masking other adhesion 
molecules on the vascular endothelium to make them less accessible to leukocyte 
integrins. HS also functions in the extracellular matrix (ECM) to retain cytokines and 
growth factors. This interaction with HS can regulate local signaling by promoting or 
inhibiting receptor-ligand interactions, and can protect cytokines from inactivation by 
proteases. The core protein of the HSPG can be cleaved by the proteases released 
during an inflammatory response to release the ectodomain and its HS chains from the 
cell surface. Heparanase can digest the HS chains to release small active fragments 
that can act as danger-associated molecular patterns (DAMPs), or continue to regulate 
the activity of HS-bound cytokines through acting as a co-receptor (promotes 
signaling) or a decoy receptor (inhibits signaling).  
 
 
Figure 3. Leukocyte HS plays many roles in immune regulation. Heparan sulfate 
proteoglycans facilitate uptake of late apopototic and necrotic cells, although the 
mechansim remains unclear. Soluble fragments of HS released during tissue 
inflammation activate cells through TLR4. HS chains on leukocyte membrane 
proteins can promote or inhibit receptor-ligand interactions for cytokines and growth 
factors. Cell-surface proteoglycans can also regulate signalling in trans by presenting 
growth factors such as FGF-2 to target cells. 
 
 
Table 1. Summary of immune-associated proteins that have been experimentally 
demonstrated to bind heparin or HS 
  
Growth factors Chemokines Cytokines 
Bone morphogenetic protein 2 (BMP-2) 
(93) 
Bone morphogenetic protein 3 (BMP-3) 
(94) 
Bone morphogenetic protein 4 (BMP-4) 
(95) 
Bone morphogenetic protein 6 (BMP-6) 
100) 
Bone morphogenetic protein 7 (BMP-7) 
(96) 
Granulocyte-macrophage colony-
stimulating factor (GM-CSF) (106) 
Connective tissue growth factor (CCN 
family member 2) (97) 
Heparin-binding growth factor 1 (HBGF-1) 
(111) 
Fibroblast growth factor 3 (FGF-3) (98) 
Fibroblast growth factor 4 (FGF-4) (99) 
Fibroblast growth factor 5 (FGF-5) (100) 
Fibroblast growth factor 6 (FGF-6) (101) 
Fibroblast growth factor 7 (FGF-7) (93) 
Fibroblast growth factor 8 (FGF-8) (102) 
(Fibroblast growth factor 9 (FGF-9) (103) 
Fibroblast growth factor 10 (FGF-10) (104) 
Fibroblast growth factor 12 (FGF-12) (105) 
Fibroblast growth factor 14 (FGF-14) (105) 
Fibroblast growth factor 16 (FGF-16) (106) 
Fibroblast growth factor 17 (FGF-17) (106) 
Fibroblast growth factor 18 (FGF-18) (106) 
Fibroblast growth factor 2 (FGF-2) (107) 
Fibroblast growth factor 20 (FGF-20) (108) 
Fibroblast growth factor 22 (FGF-22) (106) 
Proheparin-binding EGF-like growth factor 
(109) 
Platelet-derived growth factor subunit A 
(PDGF-1) (110) 
Platelet-derived growth factor subunit B 
(PDGF-2) (111) 
Placenta growth factor (PlGF) (108) 
Vascular endothelial growth factor A 
(VEGF-A) (112) 
Vascular endothelial growth factor B 
(VEGF-B) (113) 
Transforming growth factor beta-1 (TGF-
beta-1) (114) 
Transforming growth factor beta-2 (TGF-
beta-2) (114) 
Hepatoma-derived growth factor (HDGF) 
(High mobility group protein 1-like 2) (115) 
Hepatocyte growth factor (Hepatopoeitin-A) 
(116) 
C-C motif chemokine 1 (44) 
C-C motif chemokine 2 (117) 
C-C motif chemokine 3 (118) 
C-C motif chemokine 4 (119) 
C-C motif chemokine 5 (120) 
C-C motif chemokine 7 (121) 
C-C motif chemokine 8 (122) 
Eotaxin (C-C motif chemokine 11) (123) 
C-C motif chemokine 13 (124) 
C-C motif chemokine 15 (125) 
C-C motif chemokine 17 (126) 
C-C motif chemokine 19 (127) 
C-C motif chemokine 21 (126) 
C-C motif chemokine 22 (128) 
C-C motif chemokine 23 (129) 
C-C motif chemokine 24 (130) 
C-C motif chemokine 25 (127) 
C-C motif chemokine 27 (122) 
C-C motif chemokine 28 (127) 
C-X-C motif chemokine 1 (131) 
C-X-C motif chemokine 2 (132) 
C-X-C motif chemokine 4 (Platelet factor 
4) (133) 
C-X-C motif chemokine 6 (134) 
C-X-C motif chemokine 7 (131) 
C-X-C motif chemokine 8 (Interleukin-8; 
IL-8) (131) 
C-X-C motif chemokine 10 (135) 
C-X-C motif chemokine 11 (136) 
C-X-C motif chemokine 13 (127) 
C-X-C motif chemokine 16 (127) 
Interleukin-2 (IL-2) (137) 
Interleukin-3 (IL-3) (138) 
Interleukin-4 (IL-4) (139) 
Interleukin-5 (IL-5) (50) 
Interleukin-6 (IL-6) (48) 
Interleukin-7 (IL-7) (49) 
Interleukin-10 (IL-10) (78) 
Interleukin-12 subunit beta (IL-12B) (140) 
Interferon gamma (IFN-γ) (46) 
Tumor necrosis factor (TNF-α) (141) 
 
Other immune-associated proteins 
Neutrophil elastase (Elastase-2) (142) 
Basic fibroblast growth factor receptor 1 
(FGFR-1) (143) 
Fibroblast growth factor receptor 2 
(FGFR-2) (144) 
Fibroblast growth factor receptor 3 
(FGFR-3) (145) 
Fibroblast growth factor receptor 4 
(FGFR-4) (146) 
Histidine-rich glycoprotein (HRG) (147) 
Hepatic triacylglycerol lipase (Hepatic 
lipase) (148) 
Lipoprotein lipase (LPL) (149) 
L-selectin (Leukocyte adhesion molecule 
1) (150) 
P-selectin (151) 
Tenascin-C (152) 
Complement factors   
 
 
Complement factor B (153) 
Complement factor D (154) 
Complement factor H (153) 
Complement factor I (153) 
Complement factor P (properdin) (153) 
Complement component C5 (153) 
Complement component C6 (153) 
Complement component C7 (153) 
Complement component C8 alpha, beta 
and gamma chains (153) 
Complement component C9 (153) 
 
 
  
Syndecan Glypican
NHAcOH
OH OH
CH2O2COOH
O O
OOO 1
2
3
4
5
6
1
2
3
4
5
6
6-O-sulfation
2-O-sulfation 3-O-sulfation N-deacetylation/
N-sulfation
Epimerization
Glucuronic acid N-acetylglucosamine
n
Retention 
of soluble 
mediators
Regulation 
of receptor 
interactions
Release upon 
tissue injury
Protection
from 
proteolysis
Post-capillary venule
Rolling leukocyte
Endothelial 
glycocalyx 
containing 
HSPGs
Stromal cells 
and ECM
Leukocyte
Chemokines L-selectin
Chemokine 
oligomerization
Chemokine 
presentation
L-selectin 
binding
Chemokine 
immobilization 
and gradient 
formation
Regulating 
accessibility of 
adhesion 
molecules
HS core proteins ICAM-1
Vascular endothelium
Activation 
of TLR4
Phagocytosis
of dead cells
Regulation of 
cell signalling
Presentation 
of mediators
to other cells
e.g. IL-10 IFN-β
NFκB
e.g. FGF-2
Homeostasis Inflammation
This review summarizes the established and emerging roles of heparan sulfate 
as an immune regulator through its ability to bind numerous inflammatory 
ligands both in the microenvironment and on the cell-surface of leukocytes.
